By correcting one of the NADPH oxidase mutations responsible for 90% of the cases of CGD in a patient-derived iPSC line, NADPH oxidase function and cellular bacterial killing activity were restored in vitro [50]. Here, FMO5 is linked to chronic granulomatous disease.